149 related articles for article (PubMed ID: 34591291)
1. Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease.
Kaga H; Kurahashi H; Kubota A; Hatano Y; Nanjo H; Wakui H; Takahashi N
Int J Hematol; 2022 Jan; 115(1):129-134. PubMed ID: 34591291
[TBL] [Abstract][Full Text] [Related]
2. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
3. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.
Pria AD; Pinato D; Roe J; Naresh K; Nelson M; Bower M
Blood; 2017 Apr; 129(15):2143-2147. PubMed ID: 28143881
[TBL] [Abstract][Full Text] [Related]
4. Human herpesvirus 8-associated multicentric Castleman disease in a patient with advanced HIV infection: A case report.
Guayboon T; Chinthammitr Y; Sukpanichnant S; Horthongkham N; Angkasekwinai N
Medicine (Baltimore); 2021 Dec; 100(49):e28077. PubMed ID: 34889256
[TBL] [Abstract][Full Text] [Related]
5. Concurrent HIV viral blips during two episodes of multicentric Castleman disease in an adult on antiretroviral therapy: Implication for HIV persistence.
Darwish I; Costiniuk C; Kronfli N; Haegert D; Routy JP
IDCases; 2021; 26():e01315. PubMed ID: 34786336
[TBL] [Abstract][Full Text] [Related]
6. Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.
Rasmussen C; Gérard L; Fadlallah J; Corvilain E; Galicier L; Meignin V; Oksenhendler E; Boutboul D
Blood Adv; 2023 Sep; 7(18):5663-5669. PubMed ID: 37288720
[TBL] [Abstract][Full Text] [Related]
7. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.
Law AB; Ryan G; Lade S; Prince HM
Int J Hematol; 2010 Mar; 91(2):347-8; author reply 349. PubMed ID: 20146033
[No Abstract] [Full Text] [Related]
8. Human herpesvirus 8-positive multicentric Castleman disease with germinotropic plasmablastic aggregates: Overlapping spectrum of human herpesvirus 8-associated lymphoproliferative disorder.
Nakaya Y; Ishii N; Kasamatsu Y; Shimizu K; Tatsumi N; Tsutsumi M; Yoshida M; Yoshimura T; Hayashi Y; Nakao T; Inoue T; Yamane T
Pathol Int; 2020 Aug; 70(8):574-580. PubMed ID: 32449234
[TBL] [Abstract][Full Text] [Related]
9. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
Lurain K; Yarchoan R; Uldrick TS
Hematol Oncol Clin North Am; 2018 Feb; 32(1):75-88. PubMed ID: 29157621
[TBL] [Abstract][Full Text] [Related]
11. An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, who Responded well to Rituximab Alone.
Kounatidis D; Rontogianni D; Sampaziotis D; Vardaka M; Giatra C; Dolapsakis C; Margellou E; Vallianou NG
Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):84-86. PubMed ID: 30827270
[TBL] [Abstract][Full Text] [Related]
12. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
Nagao A; Nakazawa S; Hanabusa H
J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
[TBL] [Abstract][Full Text] [Related]
14. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
15. Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.
Basnayake BMDB; Wazil AWM; Kannangara T; Ratnatunga NVI; Hewamana S; Ameer AM
J Med Case Rep; 2017 May; 11(1):135. PubMed ID: 28501028
[TBL] [Abstract][Full Text] [Related]
16. Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?
Alkaied H; Harris K; Elsayegh D; Khachaturova I; Awasum M; Varma S
Med Oncol; 2012 Jun; 29(2):1109-13. PubMed ID: 21472488
[TBL] [Abstract][Full Text] [Related]
17. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease.
Stebbing J; Adams C; Sanitt A; Mletzko S; Nelson M; Gazzard B; Newsom-Davis T; Bower M
Blood; 2011 Jul; 118(2):271-5. PubMed ID: 21511959
[TBL] [Abstract][Full Text] [Related]
18. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role?
Bhanvadia V; Shet T; Rao V; Epari S; Gujral S; Jain H; Bagal B; Sengar M
Indian J Pathol Microbiol; 2021; 64(2):302-309. PubMed ID: 33851624
[TBL] [Abstract][Full Text] [Related]
19. Kaposi sarcoma herpesvirus/human herpesvirus 8-positive diffuse large B-cell lymphoma characterized by malignant ascites: A case report.
Chang LC; Fu PA; Wang SH; Chang KC; Hsu YT
Pathol Res Pract; 2024 Mar; 255():155185. PubMed ID: 38342036
[TBL] [Abstract][Full Text] [Related]
20. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
